Announcement of the Consolidated Financial
Statements for the second quarter of 2022 were approved
by the Board of Directors
Date of events
2022/08/08
To which item it meets
paragraph 31
Statement
1.Date of the board of directors submitted or approved:2022/08/08
2.Date of the audit committee approved:2022/08/08
3.Start and end dates of financial reports or unaudited financial
information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):
2022/01/01~2022/06/30
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD):3,129
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD):(23,817)
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD):(883,452)
7.Profit (loss) before tax accumulated from 1/1 to end of the period
(thousand NTD):(788,605)
8.Profit (loss) accumulated from 1/1 to end of the period
(thousand NTD):(787,159)
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD):(648,638)
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD):(3.02)
11.Total assets end of the period (thousand NTD):6,783,745
12.Total liabilities end of the period
(thousand NTD):458,362
13.Equity attributable to owners of parent end of the
period (thousand NTD):5,286,972
14.Any other matters that need to be specified:None
Attachments
Original Link
Original Document
Permalink
Disclaimer
OBI Pharma Inc. published this content on 08 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 August 2022 08:43:07 UTC.
OBI Pharma, Inc. is a Taiwan-based company principally engaged in the development of new pharmaceuticals. The Company mainly operates its businesses through the research and development of novel cancer and infectious disease therapies. It also develops next generation active immunotherapies to treat cancers, including lung, prostate, pancreatic, stomach and ovarian cancers. It is engaged in the development of OBI-822 (formerly OPT-822/821), an active immunotherapy new drug for metastatic breast cancer; the research and development of therapeutic vaccine OBI-833 for the treatment of new generation of cancers, as well as the development of cancer testing reagent OBI-868.